3
Announcements
Trials
Browse
Landscape
Status
Completed
790
Terminated
198
Unknown
104
Recruiting
103
Withdrawn
60
Active not recruiting
55
Not yet recruiting
22
No longer available
3
Suspended
2
Enrolling by invitation
2
Available
1
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Sarcoma
2
Multiple Myeloma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Thalassemia
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Metabolic Diseases
1
Mastocytosis, Systemic
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Leukemia, Plasma Cell
1
Leukemia, Mast-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Immunologic Deficiency Syndromes
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioblastoma
1
Interventions
tisagenlecleucel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Available
×
Leukemia
×
Lymphoid
×
Clear all
NCT03601442
2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available